What are BTK Inhibitors?

The purpose of BTK inhibitors is to limit CLL cells from continuously dividing and growing.

BTK, or Bruton's tyrosine kinase, is a protein found in B-cells, including dysfunctional B-cells in chronic lymphocytic leukemia (CLL). When activated, BTK triggers the replication of B-cells. This is problematic in CLL because it allows malignant CLL cells to multiply. BTK inhibitors are medications designed to block this protein, thereby preventing the replication of CLL cells.

Covalent BTK Inhibitors

Covalent BTK inhibitors bind permanently to the BTK protein, effectively stopping its activity. However, long-term use can lead to mutations in the BTK protein, causing CLL cells to become resistant to treatment.

Covalent BTK inhibitors include: 

• Ibrutinib (Imbruvica)
• Acalabrutinib (Calquence)
• Zanubrutinib (Brukinsa)

Non-Covalent BTK Inhibitors

Non-covalent BTK inhibitors temporarily bind to the BTK protein using hydrogen and ionic bonds. This binding method allows them to inhibit BTK activity even in the presence of mutations that may have developed after using covalent BTK inhibitors.

FDA-approved non-covalent BTK inhibitors include: 

• Pirtobrutinib (Jaypirca)

First, Second and Third Generation BTK Inhibitors

CLL specialists recommend second- or third-generation BTK inhibitors over the first-generation inhibitor. This preference is due to the significantly lower risk of heart-related side effects with the newer generation drugs.

• First generation: Ibrutinib 
• Second generation: Acalabrutinib or zanubrutinib
• Third generation: Pirtobrutinib

Watch our HealthTree University video below with CLL specialists explaining BTK inhibitors,  how they are used to treat CLL, and the side effects to be aware of before taking these medications. We will review all of this in greater detail in the next section.